CD274 and non-small cell lung carcinoma: (13), that survival was longer for patients with nonsquamous NSCLC with PD-L1 expression ≥50%, among whom median OS was 20.6 months (95% CI, 16.2–26.8), while for those with PD-L1 <1%, median OS was 13.2 months (95% CI, 10.9–19.9).